The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

Single-country clinical trial results: Are they applicable to other populations?

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The rapid acceleration of drug development has exponentially increased the therapeutic options available to patients with cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Edward S. Kim, MD, MBA, FACP, FASCO
Physician-in-Chief, Orange County; Vice Physician-in-Chief, City of Hope National Medical Center
Table of Contents

YOU MAY BE INTERESTED IN

White House

Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.
By Paul Goldberg
Clinical Roundup

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.
Clinical Roundup

In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds

A phase II trial found that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy. Exploratory analysis suggests greater HER2 amplification in a tumor may be associated with greater clinical benefit of dual HER2 inhibitor vs EGFR inhibitor therapy.
Clinical Roundup

Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds

In a phase Ib/II clinical trial known as EPCORE NHL-2, a team of researchers—led by Joshua Brody, director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai—showed the benefit of combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma. The results were published earlier this month in the journal Blood. 
Drugs & Targets

FDA approves Enhertu as first HER2-directed therapy for breast cancer

FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by the FDA approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
Byline
Edward S. Kim, MD, MBA, FACP, FASCO
Physician-in-Chief, Orange County; Vice Physician-in-Chief, City of Hope National Medical Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account